Latest News

Epilepsy community seeks redefinition of bioequivalence from FDA

For several years, epilepsy practitioners have questioned the U.S. Food and Drug Administration?s (FDA) definition of bioequivalence as it applies to narrow therapeutic index (NTI) drugs, such as those used for epilepsy. In response to these concerns, the FDA has sponsored 3 studies of antiepileptic drugs and also convened an advisory board to help determine which drugs are NTI.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Autism after high school: Making the transition

  • New technology shows promise for delivery of therapeutics to the brain

  • Higher suicide risk after served prison sentence

  • Major factor in development of Huntington's disease uncovered

  • Neglect of culture in medicine is 'single biggest barrier' to achieving better health

  • Different brain tumors have the same origin, new findings show

  • Politics can interact with evolution to shape human destiny

  • Heavy drinking in adolescence associated with lasting brain changes, animal study suggests

  • From age 8 to 80, expert reveals the price we pay for not sleeping

  • Evolution of competitiveness: Scientists explain diversity in competitiveness

  •